跳至主要内容
临床试验/ACTRN12618001522202
ACTRN12618001522202已完成未知

Characterisation of Glucocorticoid Toxicity and Effects on Physical Function in Newly-Diagnosed Polymyalgia Rheumatica

Austin Health0 个研究点目标入组 68 人开始时间: 2018年9月11日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
Austin Health
入组人数
68

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
50 Years 至 o limit(—)
性别
All

入选标准

  • For PMR participants:
  • Diagnosis of PMR (as defined by the 2012 EULAR/ACR Classification Criteria)
  • Commencement of prednisolone for PMR treatment <12 weeks prior
  • For control participants:
  • Age- and gender-matched to PMR participants

排除标准

  • For PMR participants:
  • Prior diagnosis or current symptoms suggestive of Giant Cell Arteritis (GCA [including headache, jaw claudication, scalp tenderness or sudden visual disturbance]);
  • Active malignancy;
  • Active infection;
  • Active neuromuscular disease;
  • Other inflammatory/autoimmune conditions requiring immunosuppression e.g. Rheumatoid Arthritis (RA);
  • Chronic pain syndromes;
  • Prior or current treatment with concomitant Disease Modifying Anti-Rheumatic Drugs (DMARD).
  • For Control Participants:
  • Current or prior diagnosis of PMR;
  • Current or prior diagnosis of GCA;
  • Any condition requiring regular systemic glucocorticoids;
  • Active malignancy;
  • Active infection;
  • Active neuromuscular disease;
  • Any inflammatory/autoimmune conditions requiring immunosuppression e.g. Rheumatoid Arthritis (RA);
  • Chronic pain syndromes.

研究者

发起方
Austin Health

相似试验